Clinical Roundup Obe-cel yields strong remission rates in adults with relapsed or refractory B-ALL in phase Ib/II study June 07, 2024Vol.50 No.23
Clinical Roundup Shorter durations of venetoclax yields similar response rates in AML June 07, 2024Vol.50 No.23
Clinical Roundup Antibody-drug conjugate targeting CEACAM5 shows activity in advanced CRC in phase I study preliminary data June 07, 2024Vol.50 No.23
Clinical Roundup USP1 inhibitor combination shows manageable safety profile, anti-tumor activity in metastatic solid tumors in phase I study preliminary data June 07, 2024Vol.50 No.23
Clinical Roundup CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data June 07, 2024Vol.50 No.23
Clinical Roundup Studies detail molecular pathway that impacts pancreatic cancer progression and response to treatment June 07, 2024Vol.50 No.23
Drugs & Targets FDA approves imetelstat for low- to intermediate-1 risk MDS with transfusion-dependent anemia June 07, 2024Vol.50 No.23
Beckerle, Ulrich, Carnival, Rathmell on navigating cancer leadership as women—and as scientists May 31, 2024Vol.50 No.22By Jacquelyn Cobb
Guest Editorial Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access May 31, 2024Vol.50 No.22By Alice L. Pomponio
